<DOC>
	<DOCNO>NCT00555100</DOCNO>
	<brief_summary>CC-5013-MM-017 Phase I , multicenter study determine maximum tolerate dose ( MTD ) , safety profile , pharmacokinetics , preliminary efficacy lenalidomide without dexamethasone Japanese subject previously treat MM . The study consist two cohort : 1 ) Monotherapy `` Maximum Tolerated Dose ( MTD ) Determination '' Cohort ; 2 ) `` Combination Treatment '' Cohort .</brief_summary>
	<brief_title>Safety Study Lenalidomide With Without Dexamethasone Japanese Subjects With Previously Treated Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subjects previously treat multiple myeloma Measurable level mprotein serum &gt; = 0.5 g/dL [ 5g/L ] ) urine ( &gt; = 0.2 g excrete 24hour collection sample ) ECOG performance status 0 2 Willing follow pregnancy precaution Patients acute myocardial infarction ( MI ) within past 6 month , patient history deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) within past 3 year Patients tuberculous disease , herpes simplex keratitis , systemic mycosis active infectious disease Patients noncontrolled diabetes , hypertension , digestive ulcer glaucoma Patients posterior subcapsular cataract Patients mental illness Patients past history complication make Investigator staff member deem inappropriate study Pregnant lactating female Grade 2 bad neuropathy Any follow laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,000cells/mL Platelet count &lt; 75,000/mL Serum creatinine &gt; 2.5 mg/dL Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) Prior history malignancy , multiple myeloma , unless subject free disease &gt; = 3 year . Patients receive radiation therapy within 14 day start study drug Patients scar recent viscus operation Patients history desquamating ( blister ) rash take thalidomide Patients prior use lenalidomide Patients know HIV positivity . Patients use cytotoxic chemotherapeutic agent , immunomodulating agent , experimental agent ( agent commercially available ) intend treatment MM within 28 day start lenalidomide therapy . Patients known history hypersensitivity dexamethasone .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>